VTRS Quote, Financials, Valuation and Earnings

Beam Therapeutics has a net margin of -93.48% compared to Viatris's net margin of -1462.79%. Viatris's return on equity of -20.24% beat Beam Therapeutics's return on equity of -43.86%.

Viatris has a consensus price target of $11.3875, signalling upside risk potential of 25.41%. On the other hand Beam Therapeutics has an analysts' consensus of $44.07 which suggests that it could grow by 119.57%. Given that Beam Therapeutics has higher upside potential than Viatris, analysts believe Beam Therapeutics is more attractive than Viatris.

Viatris has a beta of 0.896, which suggesting that the stock is 10.435% less volatile than S&P 500. In comparison Beam Therapeutics has a beta of 2.076, suggesting its more volatile than the S&P 500 by 107.573%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.29%. Beam Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Beam Therapeutics pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.3B, which are larger than Beam Therapeutics quarterly revenues of $7.5M. Viatris's net income of -$3B is lower than Beam Therapeutics's net income of -$109.3M. Notably, Viatris's price-to-earnings ratio is -- while Beam Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 26.48x for Beam Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -93.48% compared to Viatris's net margin of 21.63%. Viatris's return on equity of -20.24% beat Pfizer's return on equity of 8.72%.

Viatris has a consensus price target of $11.3875, signalling upside risk potential of 25.41%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Viatris has higher upside potential than Pfizer, analysts believe Viatris is more attractive than Pfizer.

Viatris has a beta of 0.896, which suggesting that the stock is 10.435% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.29%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Viatris pays -90.63% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Viatris quarterly revenues are $3.3B, which are smaller than Pfizer quarterly revenues of $13.7B. Viatris's net income of -$3B is lower than Pfizer's net income of $3B. Notably, Viatris's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma has a net margin of -93.48% compared to Viatris's net margin of -88.24%. Viatris's return on equity of -20.24% beat Theravance Biopharma's return on equity of -31.51%.

Viatris has a consensus price target of $11.3875, signalling upside risk potential of 25.41%. On the other hand Theravance Biopharma has an analysts' consensus of $17.20 which suggests that it could grow by 47.64%. Given that Theravance Biopharma has higher upside potential than Viatris, analysts believe Theravance Biopharma is more attractive than Viatris.

Viatris has a beta of 0.896, which suggesting that the stock is 10.435% less volatile than S&P 500. In comparison Theravance Biopharma has a beta of -0.018, suggesting its less volatile than the S&P 500 by 101.836%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.29%. Theravance Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Theravance Biopharma pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.3B, which are larger than Theravance Biopharma quarterly revenues of $15.4M. Viatris's net income of -$3B is lower than Theravance Biopharma's net income of -$13.6M. Notably, Viatris's price-to-earnings ratio is -- while Theravance Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 8.78x for Theravance Biopharma. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of -93.48% compared to Viatris's net margin of -30.29%. Viatris's return on equity of -20.24% beat Treace Medical Concepts's return on equity of -47.17%.

Viatris has a consensus price target of $11.3875, signalling upside risk potential of 25.41%. On the other hand Treace Medical Concepts has an analysts' consensus of $10.02 which suggests that it could grow by 71.23%. Given that Treace Medical Concepts has higher upside potential than Viatris, analysts believe Treace Medical Concepts is more attractive than Viatris.

Viatris has a beta of 0.896, which suggesting that the stock is 10.435% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.29%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.3B, which are larger than Treace Medical Concepts quarterly revenues of $52.6M. Viatris's net income of -$3B is lower than Treace Medical Concepts's net income of -$15.9M. Notably, Viatris's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 1.73x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.